Home LiteratureArticle Details
PMID: 26819314 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Journal of virology ·Vol. 90 ·No. 8 ·2016-04-00 ·Pages 3873-3889

Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H, Tsurumi T, Kimura H

Abstract

Latent membrane protein 1 (LMP1) is a major oncogene essential for primary B cell transformation by Epstein-Barr virus (EBV). Previous studies suggested that some transcription factors, such as PU.1, RBP-Jκ, NF-κB, and STAT, are involved in this expression, but the underlying mechanism is unclear. Here, we identified binding sites for PAX5, AP-2, and EBF in the proximal LMP1 promoter (ED-L1p). We first confirmed the significance of PU.1 and POU domain transcription factor binding for activation of the promoter in latency III. We then focused on the transcription factors AP-2 and early B cell factor (EBF). Interestingly, among the three AP-2-binding sites in the LMP1 promoter, two motifs were also bound by EBF. Overexpression, knockdown, and mutagenesis in the context of the viral genome indicated that AP-2 plays an important role in LMP1 expression in latency II in epithelial cells. In latency III B cells, on the other hand, the B cell-specific transcription factor EBF binds to the ED-L1p and activates LMP1 transcription from the promoter. Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma. Its expression is largely dependent on the cell type or condition, and some transcription factors have been implicated in its regulation. However, these previous reports evaluated the significance of specific factors mostly by reporter assay. In this study, we prepared point-mutated EBV at the binding sites of such transcription factors and confirmed the importance of AP-2, EBF, PU.1, and POU domain factors. Our results will provide insight into the transcriptional regulation of the major oncogene LMP1.

MeSH Terms
Binding Sites Cell Transformation, Viral Gene Expression Regulation, Viral HEK293 Cells HeLa Cells Herpesvirus 4, Human/genetics Humans Mutation Oncogenes POU Domain Factors/metabolism Promoter Regions, Genetic Proto-Oncogene Proteins/metabolism Trans-Activators/metabolism Transcription Factor AP-2/metabolism Viral Matrix Proteins/genetics
Chemicals
EBF1 protein, human EBV-associated membrane antigen, Epstein-Barr virus POU Domain Factors Proto-Oncogene Proteins Trans-Activators Transcription Factor AP-2 Viral Matrix Proteins proto-oncogene protein Spi-1
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Murata Takayuki
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan tmurata@med.nagoya-u.ac.jp. | Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Noda Chieko
Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Narita Yohei
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. | Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Watanabe Takahiro
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Yoshida Masahiro
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Ashio Keiji
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Sato Yoshitaka
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Goshima Fumi
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
Kanda Teru
Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan. | Division of Microbiology and Oncology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Yoshiyama Hironori
Research Center for Infection-associated Cancer, Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo, Japan. | Department of Microbiology, Shimane University Faculty of Medicine, Izumo City, Shimane, Japan.
Tsurumi Tatsuya
Division of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Kimura Hiroshi
Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
References (77)
77 references, click to expand
  1. Nasopharyngeal carcinoma.
    Orphanet J Rare Dis. 2006;1:23 PMID: 16800883
  2. LMP1 TRAFficking activates growth and survival pathways.
    Adv Exp Med Biol. 2007;597:173-87 PMID: 17633026
  3. Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation.
    Virus Genes. 2007 Oct;35(2):203-14 PMID: 17546492
  4. Modulation of LMP1 protein expression by EBV-encoded microRNAs.
    Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 PMID: 17911266
  5. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas.
    PLoS Pathog. 2007 Nov;3(11):e166 PMID: 17997602
  6. Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines.
    Virology. 2010 Apr 25;400(1):53-67 PMID: 20153012
  7. Expression of Epstein-Barr virus-encoded LMP1 and hTERT extends the life span and immortalizes primary cultures of nasopharyngeal epithelial cells.
    J Med Virol. 2010 Oct;82(10):1711-23 PMID: 20827769
  8. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.
    Blood. 2011 Jan 6;117(1):165-74 PMID: 20876453
  9. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
    Oncogene. 2011 Apr 14;30(15):1822-30 PMID: 21217775
  10. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.
    PLoS One. 2013;8(5):e63566 PMID: 23658841
  11. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2.
    Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18537-42 PMID: 24167291
  12. Overlapping expression of early B-cell factor and basic helix-loop-helix proteins as a mechanism to dictate B-lineage-specific activity of the lambda5 promoter.
    Mol Cell Biol. 2000 May;20(10):3640-54 PMID: 10779354
  13. Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.
    J Virol. 2000 Jun;74(11):5151-60 PMID: 10799590
  14. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.
    Virology. 2008 Apr 25;374(1):100-13 PMID: 18222514
  15. EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration.
    Cancer Res. 2008 Sep 1;68(17):6997-7005 PMID: 18757414
  16. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling.
    Mol Cell Biol. 2009 Jan;29(1):172-86 PMID: 18955504
  17. Transcriptional regulation of early B cell development.
    Immunol Res. 2008;42(1-3):106-17 PMID: 18818886
  18. Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.
    J Virol. 2009 Feb;83(3):1393-401 PMID: 19019967
  19. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.
    J Biol Chem. 2009 Mar 20;284(12):8033-41 PMID: 19164291
  20. The LMP1 promoter can be transactivated directly by NF-kappaB.
    J Virol. 2009 May;83(10):5269-77 PMID: 19279104
  21. Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma.
    Cancer Res. 2009 May 15;69(10):4461-7 PMID: 19435892
  22. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase.
    Virology. 2009 Jun 20;389(1-2):75-81 PMID: 19427010
  23. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.
    Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):872-7 PMID: 20080768
  24. Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency.
    J Biol Chem. 2011 Jun 24;286(25):22007-16 PMID: 21525011
  25. Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal epithelial cells.
    PLoS One. 2011;6(6):e21176 PMID: 21701587
  26. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
    Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14902-7 PMID: 21746931
  27. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines.
    J Virol. 2011 Nov;85(21):11255-64 PMID: 21849440
  28. B-lymphocyte commitment: identifying the point of no return.
    Semin Immunol. 2011 Oct;23(5):335-40 PMID: 21944938
  29. Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1.
    J Biol Chem. 2011 Dec 9;286(49):42524-33 PMID: 22013073
  30. Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.
    J Virol. 2012 Apr;86(8):4701-7 PMID: 22345482
  31. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
    J Virol. 2012 May;86(9):4752-61 PMID: 22357272
  32. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions.
    Cell Host Microbe. 2012 Aug 16;12(2):233-45 PMID: 22901543
  33. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
    J Biol Chem. 2000 Aug 4;275(31):23491-9 PMID: 10807912
  34. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control.
    Gene. 2000 Dec 30;260(1-2):1-12 PMID: 11137286
  35. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus.
    Blood. 2001 Feb 1;97(3):708-13 PMID: 11157488
  36. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors.
    J Virol. 2001 Mar;75(6):2929-37 PMID: 11222718
  37. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2.
    J Virol. 2002 Jan;76(1):232-42 PMID: 11739688
  38. SELEX and missing phosphate contact analyses reveal flexibility within the AP-2[alpha] protein: DNA binding complex.
    Nucleic Acids Res. 1999 Jul 1;27(13):2760-9 PMID: 10373594
  39. Additive effect of Sp1 and Sp3 in regulation of the ED-L1E promoter of the EBV LMP 1 gene in human epithelial cells.
    Virology. 1999 Sep 1;261(2):288-94 PMID: 10497114
  40. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses.
    Science. 1999 Oct 8;286(5438):300-3 PMID: 10514374
  41. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis.
    Oncogene. 2005 Mar 3;24(10):1711-7 PMID: 15674340
  42. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.
    PLoS Pathog. 2015 Mar;11(3):e1004656 PMID: 25790223
  43. EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jκ and EBF1.
    PLoS Pathog. 2016 Jan;12(1):e1005339 PMID: 26752713
  44. CD40 and its viral mimic, LMP1: similar means to different ends.
    Cell Signal. 2003 Jan;15(1):9-16 PMID: 12401515
  45. The significance of LMP1 expression in nasopharyngeal carcinoma.
    Semin Cancer Biol. 2002 Dec;12(6):473-87 PMID: 12450733
  46. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus.
    J Virol. 2003 Apr;77(7):4139-48 PMID: 12634372
  47. LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments.
    EMBO J. 2003 Jun 16;22(12):3027-38 PMID: 12805217
  48. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit.
    J Virol. 2003 Sep;77(17):9359-68 PMID: 12915551
  49. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system.
    J Virol. 2004 Jul;78(13):7004-15 PMID: 15194777
  50. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.
    J Virol. 1990 Jul;64(7):3407-16 PMID: 2352328
  51. Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences.
    Virology. 1993 Jul;195(1):71-80 PMID: 8391188
  52. Nasopharyngeal carcinoma: the Epstein-Barr virus association.
    Semin Oncol. 1994 Jun;21(3):376-81 PMID: 8209269
  53. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa.
    Science. 1994 Jul 1;265(5168):92-5 PMID: 8016657
  54. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein.
    Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7568-72 PMID: 8052621
  55. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1.
    J Virol. 1995 Jan;69(1):253-62 PMID: 7983717
  56. The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element.
    EMBO J. 1994 Dec 1;13(23):5624-32 PMID: 7988559
  57. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements.
    EMBO J. 1994 Dec 1;13(23):5633-8 PMID: 7988560
  58. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins.
    J Virol. 1995 Jul;69(7):4572-6 PMID: 7769726
  59. The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat.
    J Virol. 1995 Jul;69(7):4577-81 PMID: 7769727
  60. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
    J Gen Virol. 1995 Nov;76 ( Pt 11):2669-78 PMID: 7595374
  61. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter.
    J Gen Virol. 1995 Nov;76 ( Pt 11):2679-92 PMID: 7595375
  62. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.
    J Virol. 1997 Sep;71(9):6611-8 PMID: 9261383
  63. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.
    J Virol. 1997 Sep;71(9):6619-28 PMID: 9261384
  64. An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter.
    J Virol. 1998 Feb;72(2):1365-76 PMID: 9445037
  65. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.
    EMBO J. 1998 Mar 16;17(6):1700-9 PMID: 9501091
  66. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50 PMID: 9653172
  67. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice.
    Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 PMID: 9751773
  68. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation.
    FEBS Lett. 1999 Feb 5;444(1):27-31 PMID: 10037142
  69. Silencing of the Epstein-Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure.
    J Virol. 1999 Apr;73(4):2983-93 PMID: 10074148
  70. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2.
    EMBO J. 1999 May 4;18(9):2511-21 PMID: 10228165
  71. Switching of EBV cycles between latent and lytic states.
    Rev Med Virol. 2014 May;24(3):142-53 PMID: 24339346
  72. Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation.
    Cancer Med. 2014 Aug;3(4):787-95 PMID: 24799376
  73. Epstein-Barr virus oncoprotein super-enhancers control B cell growth.
    Cell Host Microbe. 2015 Feb 11;17(2):205-16 PMID: 25639793
  74. EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA.
    Cell. 2015 Feb 12;160(4):607-18 PMID: 25662012
  75. The AP-2 family of transcription factors.
    Genome Biol. 2005;6(13):246 PMID: 16420676
  76. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines.
    Blood. 2006 Apr 1;107(7):2928-35 PMID: 16332968
  77. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells.
    Int J Cancer. 2006 Oct 1;119(7):1547-52 PMID: 16671086
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2016-04-00
Epub
2016-00-28
Pages
3873-3889
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC4810554
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com